Flora Growth CORP 8-K filings

Flora Growth Corp. has finalized the first stage of its acquisition of TruHC Pharma GmbH, filing an amended 8-K to include historical financials and pro forma information.

Flora Growth Corp. has regained compliance with Nasdaq's independent director and audit committee requirements following the appointment of Brendan Cahill to its board.

Flora Growth Corp. has appointed Brendan Cahill as an independent director and member of key committees, bringing the company back into compliance with NASDAQ listing rules.

Flora Growth Corp. has entered into an agreement with Aegis Capital Corp. to potentially sell up to $3.794 million of its common shares through an at-the-market offering.

Flora Growth Corp. finalized the first stage of its acquisition of TruHC Pharma, issuing 2,770,562 common shares valued at $6.4 million.

Flora Growth Corp. has agreed to acquire TruHC Pharma GmbH for $6.4 million in a stock purchase agreement, paid in two tranches of common shares.

Flora Growth Corp. has entered into an underwriting agreement to sell 1.7 million common shares at $1.90 per share, expecting to raise approximately $2.8 million after expenses.

Flora Growth Corp. has entered into a binding letter of intent to acquire TruHC Pharma GmbH for $6.4 million in stock, pending shareholder approval and other conditions.